Companies / IMM

IMMUTEP LIMITED

ASX:IMMPharmaceuticals, Biotechnology & Life Sciences
1.47B shares on issueASX (delayed) · as of 28 July 2026$0.048price · delayed$70.7Mmarket cap · indicative
A
Dilution grade

Runway 4–8 quarters

Cash runway4.1 quarters of funding
Share-count growth (24m)1.5%
Raise cadence (24m)0 cash raises
Options & rights overhang1.1% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

IMMUTEP LIMITED's ordinary share count was 1.47B as of December 2025, up 1.5% since June 2024. The company did not raise capital in the 24-month window covered. Options and rights on issue could convert into 17M new shares, equal to 1.1% of the current share count, with 0% in the money. At the March 2026 quarter IMMUTEP reported A$102.1M in available cash, representing 4.1 quarters of cover at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.1%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
4.1 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.47B per ASX (delayed) (28 July 2026).
1.459B1.464B1.470BDec 24Sept 25July 26

Cash runway

—
Cover not computed for the latest quarter.
$102.1M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
4 Dec 20252A · quoted issueIMM : ORDINARY FULLY PAID1.47BAppendix 2A
2 Dec 20253G · unquotedORDINARY FULLY PAID1.47BAppendix 3G
13 Oct 20253G · unquotedORDINARY FULLY PAID1.47BAppendix 3G
1 Oct 20252A · quoted issueIMM : ORDINARY FULLY PAID1.47BAppendix 2A
18 July 20252A · quoted issueIMM : ORDINARY FULLY PAID1.46BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.1%
Total overhang · of current shares
0.0%
In the money · at current price
16.7M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
2 Dec 2025Dr Russell John HowardOther300k1.6M—3Y notice
2 Dec 2025Lis (Elisabeth) BoyceOther167k707k—3Y notice
1 Dec 2025Mr Pete MeyersOther———3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Abstract Accepted for Presentation at ESMO Congress 2026
14 July 2026Fourth U.S. Patent Secured for Efti and PD-1 Combination
12 July 2026$PTACTI-004 Update & Positive Mature Data from INSIGHT-003
30 June 2026Ceasing to be a substantial holder
16 June 2026Becoming a substantial holder
15 June 2026Ceasing to be a substantial holder
14 June 2026Becoming a substantial holder
9 June 2026Ceasing to be a substantial holder
9 June 2026Ceasing to be a substantial holder
8 June 2026Change in substantial holding
8 June 2026Becoming a substantial holder
4 June 2026Change in substantial holding
3 June 2026Immutep Presents Positive IMP761 Phase I Data at EULAR 2026
29 May 2026Change in substantial holding
27 May 2026Efti immune activation associated with improved survival
27 May 2026Change in substantial holding
10 May 2026Ceasing to be a substantial holder
29 Apr 2026Immutep Receives Nasdaq Notice of Bid Price Deficiency
29 Apr 2026$PImmutep Quarterly Activities Report and Appendix 4C
26 Apr 2026Change in substantial holding

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.